Connect with us

Business

Rottnest Express owner to buy main competitor SeaLink

Published

on

Rottnest Express owner to buy main competitor SeaLink

The private company that owns Rottnest Express has struck a deal to buy the SeaLink ferry business and Captain Cook Cruises, substantially boosting its share of the key market.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Tesla Stock Falls 3.2% to $348.12 as Q4 Deliveries Miss Estimates and Musk Focus Remains on AI and Robotics

Published

on

Tesla's robotaxi launch in Texas comes as Elon Musk focuses on his business ventures following his stint in Washington

Tesla Inc. (NASDAQ: TSLA) shares declined 3.2% on Monday, February 23, 2026, closing at $348.12 after trading in a range of $345.80 to $357.45. The drop came as investors digested the company’s fourth-quarter 2025 delivery figures released earlier in February and weighed ongoing uncertainty around production ramps, competition in electric vehicles, and CEO Elon Musk’s shifting priorities toward artificial intelligence and humanoid robotics.

Tesla's robotaxi launch in Texas comes as Elon Musk focuses on his business ventures following his stint in Washington
AFP

Tesla’s market capitalization stood at approximately $1.11 trillion at Monday’s close, down from peaks above $1.3 trillion in late 2025. The stock has gained roughly 4% year-to-date in 2026 but remains volatile, trading about 28% below its all-time high of $488.54 (split-adjusted) set in December 2024. Average daily volume has hovered around 85-90 million shares in recent sessions, reflecting continued retail and institutional interest despite a cooling in the meme-stock fervor of prior years.

The latest catalyst was Tesla’s Q4 2025 production and delivery report, issued February 2, 2026. The company produced 495,570 vehicles and delivered 484,507 — both figures below Wall Street consensus estimates of approximately 510,000-515,000 deliveries. Full-year 2025 deliveries totaled 1.81 million vehicles, marking the first annual decline since 2011 and falling short of Musk’s earlier goal of 20-30% growth. The shortfall was attributed to factory retooling for refreshed Model Y production, softer demand in Europe and China, and intensified competition from BYD, Rivian, and legacy automakers.

Despite the miss, Tesla maintained strong profitability metrics. Adjusted operating income reached $3.2 billion in Q4, with automotive gross margins holding above 18% excluding regulatory credits. Energy storage deployments surged 157% year-over-year to 11.0 GWh, underscoring growth in the Megapack and Powerwall businesses. Free cash flow remained positive at $2.1 billion for the quarter, supported by a cash position exceeding $33 billion.

Musk used the earnings call to pivot attention toward future growth drivers beyond EVs. He reiterated that Optimus, Tesla’s humanoid robot, represents “the biggest product opportunity in history” and projected millions of units annually within five years. The company showcased Optimus performing household tasks at the “We, Robot” event in October 2025 and confirmed limited production for internal use in 2026, with external sales targeted for 2027. Musk also highlighted progress on Full Self-Driving (FSD) software, with version 13.2 rolling out to more users and unsupervised driving demos in Texas and California.

Advertisement

Analyst reactions were mixed. Morgan Stanley maintained an Overweight rating with a $430 price target, citing robotics and AI as transformative long-term catalysts. Wedbush kept an Outperform at $515, emphasizing energy storage and autonomy upside. However, GLJ Research reiterated a Sell rating with a $23 target, arguing that current valuation assumes flawless execution on unproven initiatives while core EV growth slows. Consensus price target sits around $385-390, implying 10-12% upside from current levels, with ratings split roughly 60% Buy, 30% Hold, and 10% Sell.

The stock’s recent weakness aligns with broader EV sector pressures. Global electric vehicle sales growth has moderated in 2025-2026, with incentives phasing out in some markets and charging infrastructure still lagging in others. Tesla faces heightened competition in China, where BYD overtook it as the world’s largest EV seller by volume in 2025. Price cuts implemented in late 2025 and early 2026 helped stabilize demand but compressed margins.

Tesla’s energy business continues to shine as a bright spot. Megapack deployments are scaling rapidly, with new factories in Shanghai and Texas coming online. The segment posted record profitability in Q4, with gross margins exceeding 30%. Analysts project energy storage could contribute 15-20% of total revenue by 2027-2028 if current trends hold.

Regulatory and legal headwinds persist. The National Highway Traffic Safety Administration continues investigating FSD-related crashes, while multiple class-action lawsuits allege misleading statements about autonomy timelines. Musk’s political involvement, including his role in the Department of Government Efficiency (DOGE) under President Trump, has sparked debate about potential conflicts of interest and regulatory favoritism.

Advertisement

Looking ahead, Tesla’s next major update is the Q1 2026 production and delivery report expected in early April. Wall Street anticipates around 420,000-440,000 deliveries for the quarter, reflecting seasonal softness and ongoing Model Y refresh impacts. The earnings call, scheduled for late April, will provide further color on Optimus timelines, Robotaxi progress, and energy growth.

For now, Tesla stock trades at a forward P/E of approximately 80-90x consensus 2026 EPS estimates of $3.80-$4.00, well above traditional automakers but justified by bulls as a bet on AI, robotics, and energy rather than pure EV sales. Bears argue the multiple leaves little room for error if autonomy or humanoid timelines slip.

As February 2026 draws to a close, Tesla remains a high-conviction, high-volatility name. Its trajectory hinges on execution across multiple moonshot bets — from FSD and Robotaxi to Optimus and energy storage — while navigating a maturing EV market and macroeconomic crosscurrents.

Advertisement
Continue Reading

Business

Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50%

Published

on

Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50%

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.

Tom Little | Reuters

Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, in a bid to make the treatments more accessible to patients with insurance coverage. 

Advertisement

The obesity injection Wegovy, its new pill counterpart, the diabetes shot Ozempic and the oral diabetes drug Rybelsus will have a new lower list price of $675 per month starting on Jan. 1, 2027. The Wegovy medicines both currently have list prices of around $1,350 per month, while the diabetes drugs have list prices of around $1,027 per month.

For the first time, Novo said its price cuts are targeting insured patients whose out-of-pocket costs are linked to list prices, such as people with high-deductible health plans or co-insurance benefit designs. It’s unclear how much those patients typically pay out of pocket, but Novo says people with commercial insurance may pay as little as $25 per month for its drugs.

The Danish drugmaker has previously cut the direct-to-consumer prices of Wegovy and Ozempic, which primarily benefit cash-paying patients who often don’t have insurance coverage for the drugs. 

Novo offers its drugs to cash-paying patients for $149 to $499 per month, depending on the specific product and dose. Novo and its chief rival Eli Lilly have escalated a GLP-1 pricing war over the last year, especially following the landmark “most favored nation” deals they struck with President Donald Trump in November.

Advertisement

The move could help Novo stay more competitive with Lilly, which now holds the majority share in the blockbuster GLP-1 market. Lilly’s more effective drugs and earlier foray into the direct-to-consumer space have allowed it to take the lead in the space, but the company has yet to significantly lower the U.S. list prices of its medicines.

“Private and public payers, as well as patients, want access and have been calling for lower list prices,” Jamey Millar, Novo Nordisk’s head of U.S. operations, said in a statement. “Our actions today answer that call and remove cost barriers so the value of Wegovy and Ozempic can be realized by more patients.”

The move also coincides with new, lower Medicare prices going into effect for Novo’s obesity and diabetes drugs in 2027 following negotiations with the federal government under the Inflation Reduction Act. The new negotiated prices for Wegovy, Ozempic and Rybelsus will be $274 per month.

Advertisement
Continue Reading

Business

Energy Transfer: Continues To Dominate The Midstream Industry (NYSE:ET)

Published

on

Energy Transfer: Continues To Dominate The Midstream Industry (NYSE:ET)

This article was written by

As a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong fundamentals and good cash flows. I have a particular interest in sectors such as Oil&Gas and consumer goods. Basically, anything that has been unloved for unjustified reasons that could offer substantial returns. Energy Transfer is one of those companies that I came across when no one wanted to touch it and now I can’t resolve myself to sell it. I will always focus more on long-term value investing but I can sometimes lose myself in possible deal arbitrage such as with Microsoft/ Activision Blizzard, Spirit Airlines/Jetblue (that one still hurts), and Nippon/U.S. Steel (perfect exit at $50.19). I tend to shun businesses that I can’t understand either high-tech or certain consumer goods such as fashion (give me a Levi’s jeans). I don’t understand why anyone would invest in cryptocurrencies as well. Through Seeking Alpha, I aim to connect with like-minded investors, share insights, and build a collaborative community of individuals seeking superior returns and informed decision-making, currently on a quest to review every public company.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ET either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Data center expansion reaches an ‘inflection point’

Published

on

Data center expansion reaches an ‘inflection point’

Key Points

  • Texas is about to unseat Virginia as the world’s largest data market, according to a new report from JLL.
  • Data center vacancies at the end of 2025 remained at a historic low of 1% for the second year in a row.
  • The demand is now being driven by hyperscalers and AI, and headwinds to new development are keeping construction less robust than it could be.

Continue Reading

Business

Bars may be Mondelez’s next big platform

Published

on

Bars may be Mondelez’s next big platform

Acquisitions made since 2018 give the company a foundation in the category. 

Continue Reading

Business

Earnings call transcript: Xometry’s Q4 2025 results show strong growth, stock dips

Published

on


Earnings call transcript: Xometry’s Q4 2025 results show strong growth, stock dips

Continue Reading

Business

(VIDEO) Daniil Medvedev Cruises Past Shang Juncheng in Dominant First-Round Win at Dubai Tennis Championships

Published

on

Daniil Medvedev

DUBAI, United Arab Emirates — Daniil Medvedev wasted little time asserting dominance in the Dubai Duty Free Tennis Championships, dispatching China’s Shang Juncheng 6-1, 6-3 in straight sets Tuesday to advance to the second round of the ATP 500 event on outdoor hard courts.

The third-seeded Russian, ranked No. 11 in the world, needed just 1 hour and 6 minutes to close out the match on Centre Court at the Dubai Tennis Stadium. Medvedev fired 20 winners, including 10 aces, while winning 81% of his first-serve points and committing no double faults. Shang, ranked No. 262 and playing as a protected ranking entrant, struggled to find rhythm, managing only five winners against Medvedev’s relentless baseline pressure and precise serving.

Daniil Medvedev
Daniil Medvedev

The victory marked Medvedev’s second straight win over Shang in as many weeks. The pair met in the first round of the Qatar ExxonMobil Open in Doha on February 16, where Medvedev prevailed 6-4, 6-2. Medvedev’s flawless execution in Dubai — particularly his serve and return game — left Shang with few opportunities to mount a challenge.

Medvedev broke Shang’s serve four times across the two sets, converting on 57% of break points. Shang held serve just once in the first set and twice in the second, unable to counter Medvedev’s deep returns and aggressive court positioning. The Russian dictated play from the baseline, forcing errors and keeping rallies short when advantageous.

The match highlighted Medvedev’s strong start to 2026. After a solid Australian Open campaign and consistent results in the Middle East swing, he enters Dubai with momentum. The former world No. 1 and 2021 US Open champion won the Dubai title in 2023 and has a 4-1 record in first-round matches at the event, with no early exits since 2019.

Advertisement

Shang, a 21-year-old rising talent from China, showed flashes of potential with his quick footwork and flat groundstrokes but lacked the consistency to trouble Medvedev. The young player has climbed rankings steadily but faced a steep challenge against one of the tour’s most tactically astute competitors.

Medvedev next faces Swiss veteran Stan Wawrinka in the round of 16, setting up an intriguing clash between the 30-year-old Russian and the 40-year-old three-time Grand Slam champion. Wawrinka, a wildcard entrant, advanced earlier Tuesday with a win over another opponent.

The Dubai Duty Free Tennis Championships, featuring a strong field including top seeds and former champions, continues through March 1 with a $3,311,005 purse on hard courts. Medvedev’s efficient win keeps him on course for a deep run as he seeks to add to his Dubai legacy.

Fans can catch highlights on ATP Tour platforms and TennisTV, with live coverage available worldwide. Medvedev’s performance underscores his status as a consistent threat on hard courts, particularly in the early rounds of tournaments where his defensive prowess and counterpunching shine.

Advertisement

As the tournament progresses, Medvedev’s path could include potential quarterfinal or semifinal matchups against other seeded players. His ability to maintain focus and execute under pressure will be key in the competitive Dubai draw.

Continue Reading

Business

GLP-1 pills to shake up food and beverage landscape

Published

on

GLP-1 pills to shake up food and beverage landscape

GlobalData expects the GLP-1 pill market will grow from $3.2 billion to $34.3 billion by 2031. 

Continue Reading

Business

WBD says Paramount makes higher bid, board will weigh offer against Netflix deal

Published

on

WBD says Paramount makes higher bid, board will weigh offer against Netflix deal

An aerial view of the Paramount logo on the water tower at Paramount Studios on Feb. 23, 2026 in Los Angeles, California.

Justin Sullivan | Getty Images

Warner Bros. Discovery on Tuesday said it had received a higher takeover offer from Paramount Skydance and will review the new bid under the terms of its existing deal with Netflix.

Advertisement

Last week, WBD announced it would re-engage Paramount in deal talks under a seven-day waiver from Netflix. WBD and Netflix have an agreement to sell the legacy media group’s studio and streaming businesses to the streamer. Paramount is seeking to buy the entirety of WBD.

“Following engagement with PSKY during the seven-day limited waiver period, we received a revised PSKY proposal to acquire WBD, which we are reviewing in consultation with our financial and legal advisors,” WBD said in a statement. “We will update our shareholders following the Board’s review. The Netflix merger agreement remains in effect, and the Board continues to recommend in favor of the Netflix transaction. WBD shareholders are advised not to take any action at this time with respect to the amended PSKY tender offer.”

Paramount in a statement confirmed it had submitted a revised bid and said it will continue with its previously announced tender offer while the WBD board reviews both deals.

If WBD deems the new Paramount offer superior, Netflix will have four days to improve its previously agreed-upon bid. Netflix agreed to acquire WBD’s studio and streaming assets for $27.75 per share in December, valuing the assets around $72 billion, with a total enterprise value of approximately $82.7 billion.

Advertisement

Paramount subsequently launched a hostile tender offer to WBD shareholders for $30 per share for all of WBD, which includes linear cable networks such as CNN, TBS, HGTV and TNT and digital assets including Bleacher Report and House of Highlights.

If WBD concludes Paramount’s new offer is superior and Netflix doesn’t alter its bid, Netflix will receive a $2.8 billion breakup fee. Paramount has agreed to fund that fee as part of a previously altered hostile bid.

A combined Paramount-WBD would bring together HBO Max with Paramount+ along with merging two of the five largest movie studios by revenue — Warner Bros. and Paramount Skydance Studios. It would also put CNN and CBS News under one ownership structure.

Both the Netflix-WBD deal and a potential Paramount-WBD merger would need U.S. and European regulatory approval for completion, and both deals have raised antitrust concerns among critics.

Advertisement
Continue Reading

Business

OneMedNet secures data licensing deal with Risorius

Published

on


OneMedNet secures data licensing deal with Risorius

Continue Reading

Trending

Copyright © 2025